surmount studies tirzepatide SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants ESC 2025: post-hoc SURMOUNT-5 data
Pay in 4 interest-free payments of $5.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12




:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)























